Richard D Kim (Richard Kim)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 19

Top Topics

Locally Advanced

Circulating Tumor

Top Venues

Pragmatic and observational research

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Kimberly R Saverno, Kristin M Zimmerman Savill, Cherrishe Brown-Bickerstaff, Angele Kotomale, Michael Rodriguez, Bruce Feinberg, Haobo Ren, Mike Blecker, Richard D Kim
Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US. The oncologist (2024)
Tiago Biachi de Castria, Richard D Kim
Critique on "Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights" [Response to Letter]. Pragmatic and observational research 15 (2024)
Tiago Biachi de Castria, Richard D Kim
Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights. Pragmatic and observational research 15 (2024)
Tiago Biachi de Castria, Richard D Kim
Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights. Pragmatic and observational research 15 (2024)
Tiago Biachi de Castria, Richard D Kim
Critique on "Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights" [Response to Letter]. Pragmatic and observational research 15 (2024)
Richard D Kim, Alexis D Leal, Aparna Parikh, David P Ryan, Shining Wang, Brittany Bahamon, Neeraj Gupta, Aaron Moss, Joanna Pye, Harry Miao, Haig Inguilizian, James M Cleary
A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer chemotherapy and pharmacology (2023)
Ghassan K Abou-Alfa, Xiaoliang Wang, Christina M Parrinello, Anala Gossai, Richard D Kim, Kelly Magee, Rebecca A Miksad
Association between posttreatment α-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma. Cancer (2023)
Richard D Kim, Alexis D Leal, Aparna Parikh, David P Ryan, Shining Wang, Brittany Bahamon, Neeraj Gupta, Aaron Moss, Joanna Pye, Harry Miao, Haig Inguilizian, James M Cleary
Correction to: A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer chemotherapy and pharmacology (2023)
Richard D Kim, Alexis D Leal, Aparna Parikh, David P Ryan, Shining Wang, Brittany Bahamon, Neeraj Gupta, Aaron Moss, Joanna Pye, Harry Miao, Haig Inguilizian, James M Cleary
A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer chemotherapy and pharmacology (2023)
Canan Karan, Elaine S Tan, Humaira Sarfraz, Todd C Knepper, Christine M Walko, Seth Felder, Richard D Kim, Ibrahim Halil Sahin
Human Epidermal Growth Factor Receptor 2-Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues. JCO oncology practice 18 (8) (2022)
Elaine Tan, Junmin Whiting, Hao Xie, Iman Imanirad, Estrella Carballido, Seth Felder, Jessica Frakes, Quanxing Mo, Christine Walko, Jennifer B Permuth, Katelyn Sommerer, Richard D Kim, Daniel A Anaya, Jason B Fleming, Ibrahim Halil Sahin
BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer. The oncologist 27 (3) (2022)
Aparna Kalyan, Harshit Khosla, Richard D Kim
Immunotherapy in Biliary Tract Cancers: Where Are We? Current oncology reports 24 (12) (2022)
Rutika Mehta, Jessica Frakes, Jongphil Kim, Andrew Nixon, Yingmiao Liu, Lauren Howard, Maria E Martinez Jimenez, Estrella Carballido, Iman Imanirad, Julian Sanchez, Sophie Dessureault, Hao Xie, Seth Felder, Ibrahim Sahin, Sarah Hoffe, Mokenge Malafa, Richard D Kim
Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. The oncologist 27 (8) (2022)
Sylvia L Crowder, Aasha I Hoogland, Taylor L Welniak, Elizabeth A LaFranchise, Kristen M Carpenter, Daneng Li, Daniel M Rotroff, Arshiya Mariam, Christine M Pierce, Stacy M Fischer, Anita Y Kinney, Thi Dong-Binh Tran, Farzaneh Rastegari, Donna L Berry, Martine Extermann, Richard D Kim, Danielle B Tometich, Jane C Figueiredo, Jameel Muzaffar, Shahla Bari, Kea Turner, George M Weinstock, Heather S L Jim
Metagenomics and chemotherapy-induced nausea: A roadmap for future research. Cancer (2021)
Richard D Kim, Elaine Tan, Emily Wang, Amit Mahipal, Dung-Tsa Chen, Biwei Cao, Fadzai Masawi, Cindy Machado, James Yu, Dae Won Kim
A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. The oncologist 25 (12) (2020)
Richard D Kim, Hanna K Sanoff, Andrew S Poklepovic, Heloisa Soares, Jongphil Kim, Jing Lyu, Yingmiao Liu, Andrew B Nixon, Dae Won Kim
A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer 126 (15) (2020)
Elaine S Tan, Biwei Cao, Jongphil Kim, Taymeyah E Al-Toubah, Rutika Mehta, Barbara A Centeno, Richard D Kim
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. Cancer 127 (8) (2020)
Hao Xie, Richard D Kim
The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. Annals of surgical oncology 28 (3) (2020)
Hao Xie, Richard D Kim
ASO Author Reflections: Clinical Utility of Circulating Tumor DNA Analysis in Colorectal Cancer: Current Status. Annals of surgical oncology 27 (Suppl 3) (2020)